Therapeutic Trial of EPI -743 In Patients With Disorders of Energy Utilization or Oxidation-Reduction
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2017
At a glance
- Drugs Vatiquinone (Primary)
- Indications Metabolic disorders; Mitochondrial disorders
- Focus Therapeutic Use
- 07 Apr 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
- 04 Jan 2016 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018 as reported by ClinicalTrials.gov record.
- 19 Feb 2015 Status changed from active, no longer recruiting to recruiting, according to ClinicalTrials.gov record.